IMMUNOME - Key Persons
Prior to joining Immunome, Dr. Lechleider was the Chief Medical Officer at OncoResponse, where he oversaw the development of the company's proprietary oncology pipeline. Before OncoResponse, Dr. Lechleider served as the Senior Vice President of clinical development for Seagen, where he was responsible for directing the development of the early and late-stage portfolios, including the successful initial licensing of Padcev® for the treatment of previously treated metastatic urothelial cancer.
Bruce Turner - Chief Strategy Officer
Dr. Turner previously founded several biotechnology companies including Xanadu Bio and Gennao Bio, where he has served in executive positions including Chief Executive Officer and President. During his tenure at these companies and others he has successfully raised more than $100M of financing despite challenging market conditions. Dr. Turner previously spent 5 years at Hoffman La-Roche with increasing responsibility for drug development in the areas of metabolic diseases and oncology. Recently, Dr. Turner was a managing director at Boxer Capital of the Tavistock Group and Bank of American Merrill Lynch. Dr. Turneris the author of more than 40 publications primarily in areas of breast cancer and signal transduction. He completed his undergraduate education at the University of Chicago and graduated from University of Pennsylvania School of Medicine with M.D and Ph.D. degrees. Dr. Turner completed a residency in Radiation Oncology at Yale University.
Job Titles:
- Chairman
- Director
- Managing Partner of Hyphen Advisors
Ms. Schafer currently serves as the Managing Partner of Hyphen Advisors. Prior to Hyphen Advisors, Ms. Schafer served as Vice Chair of Wells Fargo Securities, where she led the healthcare equity capital markets team and was responsible for originating and executing equity and convertible financings. Prior to joining Wells Fargo Securities, Ms. Schafer served as Vice President of Finance and Business Development of Lexicon Pharmaceuticals. Previously, Ms. Schafer served as Managing Director, Equity Capital Markets of JPMorgan Chase working with companies in healthcare, retail, consumer and chemical industries. Ms. Schafer earned her MBA from New York University, and her BA in mathematics and computer science from Boston College. Ms. Schafer currently serves on the Board of Directors of Insmed, Repare Therapeutics and Kura Oncology, and previously served on the Board of Directors of Five Prime Therapeutics and Idera Pharmaceuticals.
Clay Siegall - CEO, Chairman, President
Job Titles:
- Chairman
- Chief Executive Officer
- Director
- President
Dr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997. Under his nearly 25 years of leadership, Seagen became the world leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue. During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company's acquisition of Cascadian Therapeutics. Pfizer, Inc. agreed to purchase Seagen for $43 billion in March 2023. Prior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and previously at the National Cancer Institute. He earned a PhD in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.
Job Titles:
- Chief Scientific Officer
- Leader
Dr. Jack Higgins is a biotechnology leader with over a decade of experience. He previously spent 11 years at Molecular Templates, Inc., serving in roles of increasing responsibility before being appointed Chief Development Sciences Officer. During his time at Molecular Templates, Dr. Higgins led discovery and development efforts for multiple clinical candidates and co-invented the company's Engineered Toxin Body (ETB) platform. Dr. Higgins completed a fellowship in tumorimmunology at the National Cancer Institute. He holds a Ph.D. and M.S from the University of Arkansas and a B.S.from Texas A&M University.
Job Titles:
- Director
- Lead Independent Director
- CEO and Co - Founder of Research Bridge Partners
Isaac Barchas is CEO and co-founder of Research Bridge Partners, a biotechnology accelerator. Barchas built RBP's team and strategy and co-manages new venture creation and investment activity. At Research Bridge Partners, Barchas has served as founding board member of Tetricus, Eradivir, and MorphImmune and as lead turnaround board member of Novosteo (NASDAQ: QNCX). Barchas is also a managing director of RBP-Catalyst Fund I and Arsenal Bridge Ventures II.
Prior to founding Research Bridge Partners, Barchas led the Austin Technology Incubator. Under Barchas' leadership, ATI companies raised $1B in investor capital. Barchas came to ATI from McKinsey & Co., where he served in the Chicago, Sydney, Auckland, and Dallas offices. Barchas served on the leadership teams of McKinsey's North American Payor/Provider and global Organization practices. Barchas received his AB from Stanford University and his Master's and JD degrees from The University of Chicago.
Job Titles:
- Director
- Chief Executive Officer of Enavate Sciences
James Boylan is Chief Executive Officer of Enavate Sciences and is an accomplished health care executive, entrepreneur, and innovator with nearly three decades of experience. Mr. Boylan most recently served as President and Head of Investment Banking of SVB Leerink, where he architected and led the firm's transformation into an industry-leading health care investment bank that was acquired by SVB Financial in 2019. Across his 12 years at SVB Leerink and prior 12 years as a Managing Director at Merrill Lynch, Mr. Boylan has worked with hundreds of life sciences and biotechnology companies to develop strategy and complete transactions in capital markets and mergers & acquisitions.
Mr. Boylan earned an M.B.A in finance from the Columbia Business School and a B.S. in finance from Lehigh University.
Jean-Jacques Bienaimé was appointed to our Board in November 2023. Mr. Bienaimé has served the CEO and a member of the board of directors of BioMarin Pharmaceutical Inc.(BioMarin), a biotechnology company focused on genetic discovery, since May 2005, and served as its chairman of the board since June 2015. Mr. Bienaimé served as Chairman, CEO, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics, from November 2002 to April 2005. Prior to Genencor, Mr. Bienaimé served as Chairman, CEO and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, from 1998 to late 2002, becoming President in 1998 and CEO in 1999. Mr. Bienaimé also held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) from 1992 to 1998, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. In addition to being a member of BioMarin's board, Mr. Bienaimé also currently serves on the board of Incyte Corporation, a public biotechnology company, and he is a member of the boards of Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA), both industry trade associations. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.
Kinney Horn has over twenty years of experience in life science finance, leadership, operations, and biopharmaceutical Business Development roles, representing over $30B in transactions. Prior to joining Immunome, Mr. Horn was Chief Business Officer of Olema Oncology, where he was part of the team that completed the company's $85M Series C crossover financing round and $240M IPO. Before Olema, he was an Entrepreneur in Residence at EcoR1 Capital.
Mr. Horn spent 16 years at Genentech, where his transaction experience included leading teams from of up to 50 employees in identifying pre-clinical and clinical stage opportunities, structuring strategic alliances, negotiating and closing deals, and managing contractual relationships. His international experience includes negotiations with European and Asian companies. In addition to corporate transaction responsibilities, he led the annual oncology strategic sourcing process for 13 areas of oncology research and development.
Prior to Roche's acquisition of Genentech, Mr. Horn worked with early-stage biotechnology companies that Genentech had invested in through GenenFUND, Genentech's private equity fund; and began his career in various investment banking and venture roles. Mr. Horn has degrees in economics, international affairs and biochemistry from Mary Washington College and Georgetown University.
Job Titles:
- Interim Chief Financial Officer and EVP, Operations
- Interim Chief Financial Officer and SVP, Operations
- Morphimmune As Acting COO
Max Rosett joined Morphimmune as Acting COO in 2022. Prior to joining Morphimmune, Mr. Rosett served as a Principal at Research Bridge Partners, where he led the Morphimmune Series A. He has over a decade of experience in data-driven roles, including time working in business operations at a Silicon Valley startup and as an engineer at Google. He started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett holds an MS from Georgia Tech and a BA in math from Yale.
Before joining Immunome, Mr. Roberts was most recently a consulting executive providing strategic and advisory support to emerging biopharmaceutical, start-up and research service companies. Prior to that, Mr. Roberts served as SVP, Technical Operations at Mirati Therapeutics where he was responsible for pharmaceutical product development, manufacturing, and supply chain operations. While at Mirati, Phil built the Tech Ops organization and led the CMC development, accelerated approval and commercialization of Mirati's first product, Krazati® (a targeted KRAS G12C inhibitor.) He has held technical and operations management positions at Avanir, Orexigen, Exelixis, Nektar, Pfizer, Roche and Eli Lilly and has successfully developed and commercialized five novel pharmaceutical products. Mr. Roberts received his M.S. in Chemical Engineering from Louisiana State University and a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute.
Mr. Wagenheim has more than 28 years of experience in the financial industry and is the Managing Partner of Broadband Capital Partners, LLC, a middle-market private equity sponsor focused on growth companies and industry consolidations. Prior to Broadband Capital Partners, he was the vice-chairman of Broadband Capital Management LLC, an investment and merchant bank he co-founded in 2000. Mr. Wagenheim has extensive experience with public and private growth equity investments, including Zynerba Pharmaceuticals (Nasdaq: ZYNE), ExamWorks (Nasdaq: EXAM), Vroom.com (Nasdaq: VRM) and Montrose Environmental Group. In connection with Zynerba's recapitalization, Mr. Wagenheim was named President and a Director of the company, serving as a director until the company's initial public offering in August 2015 led by Jefferies and Piper Jaffray. Mr. Wagenheim received his degree in Business Administration from the University of Miami.
Job Titles:
- Chief Legal Officer
- Corporate Secretary
- General Counsel
- Corporate Secretary to the Board of Directors
Sandra G. Stoneman is the Chief Legal Officer and General Counsel of Immunome. In this role, Sandra serves as Corporate Secretary to the Board of Directors and leads the legal, corporate governance, intellectual property and human resources functions of the company. Sandra structures, negotiates and documents the company's collaborations, partnerships, licenses and strategic and financing transactions. She is a seasoned legal advisor, with more than 20 years of experience advising high-growth companies in the life sciences, medical technologies and high-tech sectors. Prior to her role at Immunome, Sandra was an attorney at the law firms of Duane Morris LLP and Dechert, and is a 1997 magna cum laude graduate of Temple University School of Law, where she was an articles editor for the Temple Law Review, and a summa cum laude graduate of the State University of New York at Binghamton. Sandra has received numerous accolades for her transactional work in the life sciences field, including being continuously listed in U.S. News/Best Lawyers, Chambers USA, LMG Life Sciences and IFLR1000, and being named an Influencer of the Law by The Philadelphia Inquirer, a Best of the Bar by The Philadelphia Business Journal and a Top USA Woman Dealmaker by Global M&A Network.